ReviewThe FEBS journal2026
Behind the scenes: how the EMILIN/Multimerin family shapes the cancer landscape.
Review in The FEBS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Performance of dual-layer spectral CT-based extracellular volume fraction to assess Ki-67 proliferation status in rectal cancer: comparison with diffusion kurtosis imaging.Insights into imaging · 2026Article
- EMILIN-1 in the tumor microenvironment: insights from CNS tumors and beyond.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
In recent years, the tumor microenvironment has gained recognition as a key regulator of cancer progression. A central component of the tumor microenvironment, the extracellular matrix, undergoes dynamic remodeling during tumor development and plays a crucial role in disease pathogenesis. This review highlights the EMILIN/Multimerin family as a paradigm of the extracellular matrix's diverse and complex functions in cancer. Owing to their intricate domain architecture, these proteins engage in multifaceted interactions, not only directly modulating tumor cell proliferation and migration but also influencing other elements of the tumor microenvironment such as blood, lymphatic vessels, and immune cells. The functional landscape of these interactions is further complicated by proteolytic processing, which can both disrupt native functions and generate bioactive fragments with novel biological activities. Importantly, some of these fragments are detectable in biological fluids, suggesting their potential as predictive or prognostic biomarkers and contributing to the advancement of personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.